AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 271 min read$ABT

Ford Robert B sold $46.2M of ABT

Ford Robert B (CHAIRMAN AND CEO) sold 398,832 shares of ABBOTT LABORATORIES (ABT) at an average of $115.85 ($115.57–$116.19, $46.20M total) across 2 trades on 2026-08-25.

Original reporting
SEC EDGAR · Ford Robert B
Published Aug 27, 2026, 9:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 9:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ABT
Bearish
high confidence
Mentioned
$ABT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABTBearishMed
01

Why it matters

The sale reduces insider ownership, potentially weakening confidence among shareholders.

02

Market read

A significant insider sell by the CEO is a material event that can influence short-term price action.

03

What to watch

No 10b5-1 plan; timing may be driven by personal liquidity needs rather than negative outlook.

Relevance 7/10Novelty 8/10Timing: filed 2026-08-27

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$ABTBearishHigh confidence
Context

Chairman and CEO Robert B. Ford sold 398,832 shares for $46.2M, reducing his stake to 306,461 shares.

Expected impact

Potential short-term downside pressure as market digests the sizable sell.

Evidence & confidence

The transaction size ($46M) is material for a large-cap pharma and the insider is the CEO, making it a notable market-moving event.

Market effects

Sector

May affect perception of Abbott Laboratories' governance and could influence biotech sector sentiment.

Regional

Primarily U.S. market impact; limited regional effect.

Global

Limited to investors tracking large-cap pharma insiders.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing unrelated to company fundamentals.

Key entities

  • Executive
    Robert B. Ford

    Chairman and CEO of Abbott Laboratories

  • Company
    Abbott Laboratories

    Global healthcare and diagnostics firm

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ABT insider trading history →

Related articles

SEP 21
$ABTMedAI 8/10

NC reaches settlement with Abbott over contaminated baby formula that led to 2022 shortage

North Carolina settled with Abbott Laboratories for $384M over contaminated baby formula, part of a broader agreement with 39 states and the federal government. Abbott, which produces over 40% of U.S. formula, was accused of selling unsafe products and concealing test results. The recall caused a 2022 shortage. North Carolina's share is $216K, earmarked for Medicaid and nutrition programs.

wral.com2 min
SEP 21
$ABTHighAI 8/10

Abbott Laboratories To Pay $385M Over Allegations Of Tainted Infant Formula

Abbott Laboratories will pay $385M to resolve allegations of tainted infant formula. The settlement includes $348.7M to the federal government and $35.5M to state Medicaid programs. California's share is over $15M. The allegations span 2018-2022, involving production conditions that risked microorganism contamination. Abbott recalled several formula brands in 2022, leading to a nationwide shortage.

patch.com2 min
SEP 20
$ABTLowAI 8/10

Sunday Edition: Sodium

Abbott Laboratories agreed to pay $384.9M to settle a DOJ case over a 2022 infant formula outbreak. The settlement doesn't determine liability. Pending lawsuits remain. No specific company was named in an E. coli and Salmonella outbreak linked to seed supplier Everything Sprouts LLC. Italy's hepatitis A outbreak affected 130 people, possibly from bivalve mollusks. UK small businesses show good food safety practices but low awareness of food crime.

foodsafetynews.com4 min
SEP 20
$ABTLow

State settles infant formula contamination lawsuit, more Health Headlines

Colorado will receive nearly $2 million from Abbott Laboratories as part of a $348 million settlement over allegations of misrepresenting the safety of its infant formula, with additional $35.5 million to be split among states. The lawsuit claimed Abbott failed to maintain safety standards and disclose contamination test results. The funds will be returned to Colorado's Medicaid program.

gjsentinel.com2 min
SEP 19
$ABTMedAI 8/10

Abbott Laboratories Pays 384 Million In Baby Formula Safety Settlement

Abbott Laboratories (ABT) will pay $384 million to settle a lawsuit alleging it failed to maintain safety standards in its baby formula manufacturing facilities from 2018 to 2022, according to New York Attorney General Letitia James. The settlement includes $348 million to the federal government and $35 million to a coalition of states, with New York receiving $9.3 million. The lawsuit claimed Abbott's practices put products at risk of contamination and misled safety inspectors.

wpdh.com2 min